Year To Quarter End Consolidated Statement Of Income

ASKA Pharmaceutical Holdings CO., Ltd. - Filing #7539685

Concept 2023-04-01 to
2023-09-30
2023-04-01 to
2023-09-30
2023-04-01 to
2023-09-30
2023-04-01 to
2023-09-30
2023-04-01 to
2023-09-30
2023-04-01 to
2023-09-30
2022-04-01 to
2022-09-30
2022-04-01 to
2022-09-30
2022-04-01 to
2022-09-30
2022-04-01 to
2022-09-30
2022-04-01 to
2022-09-30
2022-04-01 to
2022-09-30
Year to quarter end consolidated statement of income
Statement of income
Net sales
3,162,000,000 JPY
31,675,000,000 JPY
28,404,000,000 JPY
31,648,000,000 JPY
-27,000,000 JPY
108,000,000 JPY
3,234,000,000 JPY
26,851,000,000 JPY
-28,000,000 JPY
114,000,000 JPY
30,200,000,000 JPY
30,172,000,000 JPY
Cost of sales
16,461,000,000 JPY
15,870,000,000 JPY
Gross profit (loss)
15,186,000,000 JPY
14,301,000,000 JPY
Selling, general and administrative expenses
Selling, general and administrative expenses
12,130,000,000 JPY
11,422,000,000 JPY
Operating profit (loss)
44,000,000 JPY
3,641,000,000 JPY
3,658,000,000 JPY
3,055,000,000 JPY
-585,000,000 JPY
-61,000,000 JPY
231,000,000 JPY
3,141,000,000 JPY
-473,000,000 JPY
-20,000,000 JPY
3,352,000,000 JPY
2,879,000,000 JPY
Non-operating income
Interest income
2,000,000 JPY
0 JPY
Dividend income
187,000,000 JPY
185,000,000 JPY
Non-operating income
224,000,000 JPY
236,000,000 JPY
Non-operating expenses
Interest expenses
21,000,000 JPY
25,000,000 JPY
Non-operating expenses
183,000,000 JPY
128,000,000 JPY
Ordinary profit (loss)
3,096,000,000 JPY
2,987,000,000 JPY
Extraordinary income
Extraordinary income
2,314,000,000 JPY
32,000,000 JPY
Profit (loss) before income taxes
5,410,000,000 JPY
3,019,000,000 JPY
Income taxes - current
1,424,000,000 JPY
693,000,000 JPY
Income taxes - deferred
-143,000,000 JPY
-19,000,000 JPY
Income taxes
1,280,000,000 JPY
673,000,000 JPY
Profit (loss)
4,129,000,000 JPY
2,346,000,000 JPY
Profit attributable to
Profit (loss) attributable to owners of parent
4,129,000,000 JPY
2,346,000,000 JPY
Other comprehensive income
Valuation difference on available-for-sale securities
-134,000,000 JPY
519,000,000 JPY
Remeasurements of defined benefit plans, net of tax
-15,000,000 JPY
13,000,000 JPY
Share of other comprehensive income of entities accounted for using equity method
271,000,000 JPY
371,000,000 JPY
Other comprehensive income
121,000,000 JPY
905,000,000 JPY
Comprehensive income
4,251,000,000 JPY
3,251,000,000 JPY
Comprehensive income attributable to
Comprehensive income attributable to owners of parent
4,251,000,000 JPY
3,251,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.